{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:44:57Z","timestamp":1794257097068,"version":"4.9.0"},"reference-count":87,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,25]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Natural killer (NK) cells play an integral role in immunosurveillance against myeloid malignancies, with their mature phenotype and abundance linked to prolonged treatment-free remission in chronic myeloid leukemia (CML). However, NK cell function is suppressed during the disease, and the orchestrators of this impairment are not fully understood. Using a chimeric BCR::ABL1+ CML mouse model, we characterized the impact of the leukemic microenvironment on NK cell function. We showed that NK cells have reduced counts, immature phenotype, poor cytotoxicity, and altered expression of activating and inhibitory receptors in CML mice, which revert to a steady state upon BCR::ABL1 inhibition. Single-cell RNA sequencing revealed an inflammatory cytokine response in CML-exposed NK cells, highlighted by the tumor necrosis factor \u03b1 (TNF\u03b1)-induced gene signature, upregulation of TNF\u03b1 receptor 2, and enrichment of suppressor of cytokine signaling family genes such as Cish, the critical NK cell checkpoint. Ex\u00a0vivo exposure of healthy NK cells to leukemic soluble factors compromised target-specific NK cell degranulation, which was partially rescued by targeting Cish or TNF\u03b1. In alignment with these findings, NK cells from healthy donors displayed suppressed cytotoxicity when exposed to plasma from untreated patients with CML, with a partial restoration upon Cish or TNF\u03b1 inhibition. Furthermore, NK cells from newly diagnosed patients with CML predestined for blast crisis showed an enrichment of the TNF\u03b1-induced proinflammatory gene signature identified in CML mice. These results suggest that targeting inflammatory signaling could enhance NK cell-based immunotherapies for CML.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014592","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T22:01:40Z","timestamp":1732226500000},"page":"759-773","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["Chronic inflammation deters natural killer cell fitness and cytotoxicity in myeloid leukemia"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1329-4736","authenticated-orcid":false,"given":"Valeriya","family":"Kuznetsova","sequence":"first","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5028-6567","authenticated-orcid":false,"given":"Vaidehi","family":"Krishnan","sequence":"additional","affiliation":[{"name":"2Cancer and Stem Cell Biology Research Program, Duke-National University of Singapore Graduate Medical School, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1898-2896","authenticated-orcid":false,"given":"Amanda","family":"Costa","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL"},{"name":"3Hematology Division, Department of Medical Imaging, Hematology, and Clinical Oncology, Ribeir\u00e3o Preto Medical School, University of S\u00e3o Paulo, Ribeir\u00e3o Preto, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8349-3960","authenticated-orcid":false,"given":"Xi","family":"Ren","sequence":"additional","affiliation":[{"name":"4Laboratory of Systems Biology and Data Analytics, Genome Institute of Singapore, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3506-3103","authenticated-orcid":false,"given":"Tiffany D.","family":"Ricketts","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7082-7204","authenticated-orcid":false,"given":"Sweta B.","family":"Patel","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL"},{"name":"5Division of Hematology, Department of Medicine, Anschutz Medical Campus, University of Colorado, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3257-487X","authenticated-orcid":false,"given":"Ashley N.","family":"Connelly","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6494-632X","authenticated-orcid":false,"given":"Paran","family":"Goel","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua P.","family":"Knapp","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1895-5337","authenticated-orcid":false,"given":"Alana M.","family":"Franceski","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8431-475X","authenticated-orcid":false,"given":"Francesca","family":"Luca","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2139-5756","authenticated-orcid":false,"given":"Lorena","family":"Lobo de Figueiredo-Pontes","sequence":"additional","affiliation":[{"name":"3Hematology Division, Department of Medical Imaging, Hematology, and Clinical Oncology, Ribeir\u00e3o Preto Medical School, University of S\u00e3o Paulo, Ribeir\u00e3o Preto, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Bhatia","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam","family":"Prabhakar","sequence":"additional","affiliation":[{"name":"4Laboratory of Systems Biology and Data Analytics, Genome Institute of Singapore, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9460-3483","authenticated-orcid":false,"given":"S. Tiong","family":"Ong","sequence":"additional","affiliation":[{"name":"2Cancer and Stem Cell Biology Research Program, Duke-National University of Singapore Graduate Medical School, Singapore, Singapore"},{"name":"6Department of Haematology, Singapore General Hospital, Singapore, Singapore"},{"name":"7Division of Medical Oncology, National Cancer Centre, Singapore, Singapore"},{"name":"8Department of Medicine, Duke University Medical Center, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Welner","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"issue":"1","key":"2025032418275402800_bib1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/asheducation-2014.1.287","article-title":"The evolving genomic landscape of myeloproliferative neoplasms","volume":"2014","author":"Nangalia","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2025032418275402800_bib2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3389\/fimmu.2017.00469","article-title":"Immune effector recovery in chronic myeloid leukemia and treatment-free remission","volume":"8","author":"Hughes","year":"2017","journal-title":"Front Immunol"},{"issue":"1","key":"2025032418275402800_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11899-013-0190-1","article-title":"Immunology and immunotherapy of chronic myeloid leukemia","volume":"9","author":"Ilander","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"issue":"9584","key":"2025032418275402800_bib4","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"Chronic myeloid leukaemia","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"2025032418275402800_bib5","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41375-021-01238-w","article-title":"Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape","volume":"35","author":"Hsieh","year":"2021","journal-title":"Leukemia"},{"key":"2025032418275402800_bib6","doi-asserted-by":"crossref","first-page":"102421","DOI":"10.1016\/j.ejon.2023.102421","article-title":"Chronic myeloid leukaemia: a qualitative interview study exploring disease impact from patient and practitioner perspectives","volume":"67","author":"Hewison","year":"2023","journal-title":"Eur J Oncol Nurs"},{"issue":"1","key":"2025032418275402800_bib7","doi-asserted-by":"crossref","first-page":"e004266","DOI":"10.1136\/bmjopen-2013-004266","article-title":"Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort","volume":"4","author":"Smith","year":"2014","journal-title":"BMJ Open"},{"issue":"12","key":"2025032418275402800_bib8","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.3324\/haematol.2019.240739","article-title":"Why is it critical to achieve a deep molecular response in chronic myeloid leukemia?","volume":"105","author":"Branford","year":"2020","journal-title":"Haematologica"},{"issue":"9","key":"2025032418275402800_bib9","doi-asserted-by":"crossref","first-page":"984","DOI":"10.6004\/jnccn.2009.0065","article-title":"NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia","volume":"7","author":"O'Brien","year":"2009","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"11","key":"2025032418275402800_bib10","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"10","key":"2025032418275402800_bib11","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ajh.24120","article-title":"Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study","volume":"90","author":"Mori","year":"2015","journal-title":"Am J Hematol"},{"issue":"22","key":"2025032418275402800_bib12","doi-asserted-by":"crossref","first-page":"6606","DOI":"10.1158\/1078-0432.CCR-18-3373","article-title":"Evaluation of residual disease and TKI duration are critical predictive factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients","volume":"25","author":"Nicolini","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2025032418275402800_bib13","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2025032418275402800_bib14","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"issue":"6","key":"2025032418275402800_bib15","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1159\/000525935","article-title":"Treatment-free remission in real-world chronic myeloid leukemia patients: insights from German hematology practices","volume":"145","author":"Dengler","year":"2022","journal-title":"Acta Haematol"},{"issue":"10","key":"2025032418275402800_bib16","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.3324\/haematol.2021.280175","article-title":"Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study","volume":"107","author":"Gugliotta","year":"2022","journal-title":"Haematologica"},{"issue":"7","key":"2025032418275402800_bib17","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ajh.26550","article-title":"Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors","volume":"97","author":"Haddad","year":"2022","journal-title":"Am J Hematol"},{"issue":"5","key":"2025032418275402800_bib18","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1158\/1535-7163.MCT-22-0146","article-title":"Correction: HLA polymorphisms are associated with treatment-free remission following discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"21","author":"Ureshino","year":"2022","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"2025032418275402800_bib19","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/s12185-023-03549-3","article-title":"Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study","volume":"117","author":"Yoshida","year":"2023","journal-title":"Int J Hematol"},{"issue":"8","key":"2025032418275402800_bib20","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3324\/haematol.2017.165001","article-title":"Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study","volume":"102","author":"Rea","year":"2017","journal-title":"Haematologica"},{"issue":"5","key":"2025032418275402800_bib21","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/leu.2016.360","article-title":"Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia","volume":"31","author":"Ilander","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"2025032418275402800_bib22","first-page":"42","article-title":"Identification of immunological parameters as predictive biomarkers of relapse in patients with chronic myeloid leukemia on treatment-free remission","volume":"10","author":"Vigon","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"2025032418275402800_bib23","doi-asserted-by":"crossref","first-page":"1241600","DOI":"10.3389\/fimmu.2023.1241600","article-title":"In-depth characterization of NK cell markers from CML patients who discontinued tyrosine kinase inhibitor therapy","volume":"14","author":"Sanchez","year":"2023","journal-title":"Front Immunol"},{"issue":"12","key":"2025032418275402800_bib24","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","article-title":"Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial","volume":"2","author":"Imagawa","year":"2015","journal-title":"Lancet Haematol"},{"issue":"3","key":"2025032418275402800_bib25","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/bjh.16718","article-title":"Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells","volume":"191","author":"Irani","year":"2020","journal-title":"Br J Haematol"},{"issue":"8","key":"2025032418275402800_bib26","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1111\/cas.14518","article-title":"Silent NK\/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment-free remission","volume":"111","author":"Kumagai","year":"2020","journal-title":"Cancer Sci"},{"issue":"5","key":"2025032418275402800_bib27","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat Immunol"},{"issue":"8","key":"2025032418275402800_bib28","doi-asserted-by":"crossref","first-page":"e20231222","DOI":"10.1084\/jem.20231222","article-title":"Five decades of natural killer cell discovery","volume":"221","author":"Lanier","year":"2024","journal-title":"J\u00a0Exp Med"},{"issue":"8000","key":"2025032418275402800_bib29","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","article-title":"Natural killer cell therapies","volume":"626","author":"Vivier","year":"2024","journal-title":"Nature"},{"issue":"19","key":"2025032418275402800_bib30","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1182\/blood-2010-04-281675","article-title":"Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education","volume":"116","author":"Bjorkstrom","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2025032418275402800_bib31","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","article-title":"The biology of human natural killer-cell subsets","volume":"22","author":"Cooper","year":"2001","journal-title":"Trends Immunol"},{"issue":"3","key":"2025032418275402800_bib32","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/leu.2011.239","article-title":"NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice","volume":"26","author":"Chen","year":"2012","journal-title":"Leukemia"},{"key":"2025032418275402800_bib33","doi-asserted-by":"crossref","first-page":"9531549","DOI":"10.1155\/2020\/9531549","article-title":"Increased expression of TIGIT\/CD57 in peripheral blood\/bone marrow NK cells in patients with chronic myeloid leukemia","volume":"2020","author":"Yao","year":"2020","journal-title":"Biomed Res Int"},{"issue":"9","key":"2025032418275402800_bib34","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2025032418275402800_bib35","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/leu.2009.46","article-title":"Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy","volume":"23","author":"Mustjoki","year":"2009","journal-title":"Leukemia"},{"issue":"22","key":"2025032418275402800_bib36","first-page":"2738","article-title":"A\u00a0single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia","volume":"141","author":"Krishnan","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2025032418275402800_bib37","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41375-023-02074-w","article-title":"Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation","volume":"38","author":"Huuhtanen","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"2025032418275402800_bib38","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1182\/blood-2003-12-4369","article-title":"Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis","volume":"105","author":"Koschmieder","year":"2005","journal-title":"Blood"},{"issue":"5","key":"2025032418275402800_bib39","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ccell.2015.04.004","article-title":"Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells","volume":"27","author":"Welner","year":"2015","journal-title":"Cancer Cell"},{"issue":"1","key":"2025032418275402800_bib40","doi-asserted-by":"crossref","first-page":"e157421","DOI":"10.1172\/jci.insight.157421","article-title":"Low c-Kit expression identifies primitive, therapy-resistant CML stem cells","volume":"8","author":"Shah","year":"2023","journal-title":"JCI Insight"},{"issue":"355","key":"2025032418275402800_bib41","doi-asserted-by":"crossref","first-page":"355ra117","DOI":"10.1126\/scitranslmed.aag1180","article-title":"Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells","volume":"8","author":"Carter","year":"2016","journal-title":"Sci Transl Med"},{"issue":"23","key":"2025032418275402800_bib42","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1182\/blood-2015-11-679928","article-title":"Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells","volume":"128","author":"Zhang","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2025032418275402800_bib43","first-page":"216","article-title":"Ontogeny of natural killer cells and T cells by analysis of BCR-ABL rearrangement from patients with chronic myelogenous leukaemia","volume":"111","author":"Cho","year":"2000","journal-title":"Br J Haematol"},{"issue":"2-3","key":"2025032418275402800_bib44","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000039748","article-title":"Detection of the BCR-ABL fusion gene in natural killer cells in patients with chronic myelogenous leukemia","volume":"104","author":"Min","year":"2000","journal-title":"Acta Haematol"},{"issue":"3","key":"2025032418275402800_bib45","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cytogfr.2013.03.005","article-title":"Suppression of cytokine signaling: the SOCS perspective","volume":"24","author":"Linossi","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"issue":"7","key":"2025032418275402800_bib46","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ni.3470","article-title":"CIS is a potent checkpoint in NK cell\u2013mediated tumor immunity","volume":"17","author":"Delconte","year":"2016","journal-title":"Nat Immunol"},{"issue":"13","key":"2025032418275402800_bib47","doi-asserted-by":"crossref","first-page":"7093","DOI":"10.3390\/ijms22137093","article-title":"Targeting leukemic stem cells in chronic myeloid leukemia: is it worth the effort?","volume":"22","author":"Soverini","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"24","key":"2025032418275402800_bib48","first-page":"5831","article-title":"Extramedullary hematopoiesis of the liver and spleen","volume":"10","author":"Cenariu","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"22","key":"2025032418275402800_bib49","doi-asserted-by":"crossref","first-page":"5488","DOI":"10.1182\/blood-2008-10-187179","article-title":"Maturation of mouse NK cells is a 4-stage developmental program","volume":"113","author":"Chiossone","year":"2009","journal-title":"Blood"},{"issue":"8","key":"2025032418275402800_bib50","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.4049\/jimmunol.178.8.4764","article-title":"NK cell maturation and peripheral homeostasis is associated with KLRG1 up-regulation","volume":"178","author":"Huntington","year":"2007","journal-title":"J\u00a0Immunol"},{"issue":"10","key":"2025032418275402800_bib51","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.3390\/cancers13102385","article-title":"Acute myeloid leukemia: is it T time?","volume":"13","author":"Ben Khoud","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"2025032418275402800_bib52","doi-asserted-by":"crossref","first-page":"18012","DOI":"10.1038\/s41598-021-97400-6","article-title":"DNAM-1\/CD226 is functionally expressed on acute myeloid leukemia (AML) cells and is associated with favorable prognosis","volume":"11","author":"Chashchina","year":"2021","journal-title":"Sci Rep"},{"issue":"9","key":"2025032418275402800_bib53","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1038\/leu.2010.149","article-title":"Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome","volume":"24","author":"Carlsten","year":"2010","journal-title":"Leukemia"},{"issue":"5","key":"2025032418275402800_bib54","doi-asserted-by":"crossref","first-page":"e004244","DOI":"10.1136\/jitc-2021-004244","article-title":"Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity","volume":"10","author":"Bernard","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"issue":"suppl 2","key":"2025032418275402800_bib55","first-page":"A123","article-title":"113 CISH gene-knockout anti-CD70-CAR NK cells demonstrate potent anti-tumor activity against solid tumor cell lines and provide partial resistance to tumor microenvironment inhibition","volume":"9","author":"Guo","year":"2021","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"2","key":"2025032418275402800_bib56","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.stem.2020.05.008","article-title":"Metabolic reprograming via deletion of CISH in human iPSC-derived NK cells promotes in\u00a0vivo persistence and enhances anti-tumor activity","volume":"27","author":"Zhu","year":"2020","journal-title":"Cell Stem Cell"},{"issue":"7994","key":"2025032418275402800_bib57","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41586-023-06816-9","article-title":"Dictionary of immune responses to cytokines at single-cell resolution","volume":"625","author":"Cui","year":"2024","journal-title":"Nature"},{"issue":"6","key":"2025032418275402800_bib58","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/leu.2016.34","article-title":"TGF-\u03b1 and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy","volume":"30","author":"Nievergall","year":"2016","journal-title":"Leukemia"},{"issue":"4","key":"2025032418275402800_bib59","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/(SICI)1099-1069(199812)16:4<143::AID-HON628>3.0.CO;2-U","article-title":"Abnormal levels of proinflammatory cytokines in serum and monocyte cultures from patients with chronic myeloid leukemia in different stages, and their role in prognosis","volume":"16","author":"Anand","year":"1998","journal-title":"Hematol Oncol"},{"issue":"9","key":"2025032418275402800_bib60","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1182\/blood.V84.9.3142.3142","article-title":"Altered levels of interleukin-1 beta and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates","volume":"84","author":"Wetzler","year":"1994","journal-title":"Blood"},{"issue":"2","key":"2025032418275402800_bib61","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s11899-015-0255-4","article-title":"Targeting the microenvironment in acute myeloid leukemia","volume":"10","author":"Rashidi","year":"2015","journal-title":"Curr Hematol Malig Rep"},{"issue":"10","key":"2025032418275402800_bib62","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1038\/bjc.2017.316","article-title":"Circulating cytokines and small molecules follow distinct expression patterns in acute myeloid leukaemia","volume":"117","author":"Islam","year":"2017","journal-title":"Br J Cancer"},{"issue":"4","key":"2025032418275402800_bib63","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1038\/s41596-020-0292-x","article-title":"CellPhoneDB: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes","volume":"15","author":"Efremova","year":"2020","journal-title":"Nat Protoc"},{"key":"2025032418275402800_bib64","doi-asserted-by":"crossref","first-page":"730970","DOI":"10.3389\/fimmu.2021.730970","article-title":"Chronic IL-15 stimulation and impaired mTOR signaling and metabolism in natural killer cells during acute myeloid leukemia","volume":"12","author":"Bou-Tayeh","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"2025032418275402800_bib65","doi-asserted-by":"crossref","first-page":"e96219","DOI":"10.1172\/jci.insight.96219","article-title":"Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect","volume":"3","author":"Felices","year":"2018","journal-title":"JCI Insight"},{"issue":"3","key":"2025032418275402800_bib66","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41590-020-00850-9","article-title":"IL-2 regulates tumor-reactive CD8+ T cell exhaustion by activating the aryl hydrocarbon receptor","volume":"22","author":"Liu","year":"2021","journal-title":"Nat Immunol"},{"issue":"14","key":"2025032418275402800_bib67","doi-asserted-by":"crossref","first-page":"e127729","DOI":"10.1172\/jci.insight.127729","article-title":"Regulation of murine NK cell exhaustion through the activation of the DNA damage repair pathway","volume":"5","author":"Alvarez","year":"2019","journal-title":"JCI Insight"},{"issue":"3","key":"2025032418275402800_bib68","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1182\/blood.V89.3.910","article-title":"Cytokine-induced apoptosis of human natural killer cells identifies a novel mechanism to regulate the innate immune response","volume":"89","author":"Ross","year":"1997","journal-title":"Blood"},{"issue":"1","key":"2025032418275402800_bib69","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1186\/s13046-019-1310-0","article-title":"IL-6 and IL-8 secreted by tumour cells impair the function of NK cells via the STAT3 pathway in oesophageal squamous cell carcinoma","volume":"38","author":"Wu","year":"2019","journal-title":"J\u00a0Exp Clin Cancer Res"},{"issue":"7","key":"2025032418275402800_bib70","doi-asserted-by":"crossref","first-page":"864","DOI":"10.4014\/jmb.2304.04023","article-title":"Role of interleukin(IL)-6 in NK activity to hypoxic-induced highly invasive hepatocellular carcinoma(HCC) cells","volume":"33","author":"Lee","year":"2023","journal-title":"J\u00a0Microbiol Biotechnol"},{"issue":"1","key":"2025032418275402800_bib71","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cmet.2017.05.018","article-title":"IL-6\/Stat3-dependent induction of a distinct, obesity-associated NK cell subpopulation deteriorates energy and glucose homeostasis","volume":"26","author":"Theurich","year":"2017","journal-title":"Cell Metab"},{"issue":"8","key":"2025032418275402800_bib72","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.amjcard.2003.12.054","article-title":"Interleukin-6 (IL-6) expression and natural killer (NK) cell dysfunction and anergy in heart failure","volume":"93","author":"Vredevoe","year":"2004","journal-title":"Am J Cardiol"},{"issue":"9","key":"2025032418275402800_bib73","doi-asserted-by":"crossref","first-page":"4694","DOI":"10.1172\/JCI138554","article-title":"Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent","volume":"130","author":"Mazzoni","year":"2020","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"2025032418275402800_bib74","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1365-2567.2011.03446.x","article-title":"CD11b and CD27 reflect distinct population and functional specialization in human natural killer cells","volume":"133","author":"Fu","year":"2011","journal-title":"Immunology"},{"issue":"2","key":"2025032418275402800_bib75","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41592-019-0667-5","article-title":"NicheNet: modeling intercellular communication by linking ligands to target genes","volume":"17","author":"Browaeys","year":"2020","journal-title":"Nat Methods"},{"issue":"17","key":"2025032418275402800_bib76","doi-asserted-by":"crossref","first-page":"e152585","DOI":"10.1172\/JCI152585","article-title":"IFN-\u03b1 with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia","volume":"132","author":"Huuhtanen","year":"2022","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"2025032418275402800_bib77","first-page":"1","article-title":"SOCS proteins in development and disease","volume":"2","author":"Trengove","year":"2013","journal-title":"Am J Clin Exp Immunol"},{"issue":"5","key":"2025032418275402800_bib78","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.2020007748","article-title":"Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells","volume":"137","author":"Daher","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2025032418275402800_bib79","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12967-019-1917-0","article-title":"TNF-\u03b1-induced Tim-3 expression marks the dysfunction of infiltrating natural killer cells in human esophageal cancer","volume":"17","author":"Zheng","year":"2019","journal-title":"J\u00a0Transl Med"},{"key":"2025032418275402800_bib80","doi-asserted-by":"crossref","first-page":"102409","DOI":"10.1016\/j.coi.2023.102409","article-title":"Molecular mechanisms of tumour necrosis factor signalling via TNF receptor 1 and TNF receptor 2 in the tumour microenvironment","volume":"86","author":"Alim","year":"2024","journal-title":"Curr Opin Immunol"},{"issue":"12","key":"2025032418275402800_bib81","doi-asserted-by":"crossref","first-page":"e1386826","DOI":"10.1080\/2162402X.2017.1386826","article-title":"TNFR2\/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer","volume":"7","author":"Ivagnes","year":"2018","journal-title":"OncoImmunology"},{"issue":"10","key":"2025032418275402800_bib82","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/s41423-023-01071-4","article-title":"The TNF\u03b1\/TNFR2 axis mediates natural killer cell proliferation by promoting aerobic glycolysis","volume":"20","author":"Khan","year":"2023","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"2025032418275402800_bib83","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3324\/haematol.2022.280922","article-title":"Targeting cytokine-induced leukemic stem cell persistence in chronic myeloid leukemia by IKK2-inhibition","volume":"108","author":"Butow","year":"2023","journal-title":"Haematologica"},{"issue":"7","key":"2025032418275402800_bib84","doi-asserted-by":"crossref","first-page":"e20201541","DOI":"10.1084\/jem.20201541","article-title":"Inflammation as a regulator of hematopoietic stem cell function in disease, aging, and clonal selection","volume":"218","author":"Caiado","year":"2021","journal-title":"J\u00a0Exp Med"},{"issue":"7","key":"2025032418275402800_bib85","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1182\/blood.V92.7.2338","article-title":"MCP-1, not MIP-1alpha, is the endogenous chemokine that cooperates with TGF-beta to inhibit the cycling of primitive normal but not leukemic (CML) progenitors in long-term human marrow cultures","volume":"92","author":"Cashman","year":"1998","journal-title":"Blood"},{"issue":"1","key":"2025032418275402800_bib86","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41467-021-27928-8","article-title":"Eliminating chronic myeloid leukemia stem cells by IRAK1\/4 inhibitors","volume":"13","author":"Tanaka","year":"2022","journal-title":"Nat Commun"},{"issue":"4","key":"2025032418275402800_bib87","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/cancers10040104","article-title":"The critical role of inflammation in the pathogenesis and progression of myeloid malignancies","volume":"10","author":"Craver","year":"2018","journal-title":"Cancers"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/4\/759\/2355908\/blooda_adv-2024-014592-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/4\/759\/2355908\/blooda_adv-2024-014592-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T21:09:19Z","timestamp":1742850559000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/4\/759\/526103\/Chronic-inflammation-deters-natural-killer-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":87,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,2,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014592","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]}}}